Document is current
Any future updates will be listed below
-
Authors
Sheiban, Francesco Jamal https://orcid.org/0000-0002-2297-0222
Antonietti, Alberto https://orcid.org/0000-0003-0388-6321
Beyazyüz, Muhammed Furkan https://orcid.org/0000-0002-5314-2649
De Schepper, Robin https://orcid.org/0000-0001-8224-9341
Alonso-Martínez, Carmen
Rubio-Teves, Mario
Clascá, Francisco https://orcid.org/0000-0003-0718-1337
D’Angelo, Egidio
Pedrocchi, Alessandra https://orcid.org/0000-0001-9957-2786
- License Information
-
More Information
Article History
Received: 16 April 2025
Accepted: 30 March 2026
First Online: 18 April 2026
Competing interests
: A.P. is co-founder of Agade Srl and AllyArm Srl; has conducted seminars for Novartis, Pfizer, TEHA, and Accmed; and has received research funding from international bodies (EU FP7, Horizon/HE, NIH, ESA), national public institutions (MIUR PRIN, INAIL, Lombardy Region, ASI), private foundations (Fondazione Cariplo, Fondazione Telethon, Fondazione Valduce, Fondazione FORST), and companies (Kayser Italia Srl, Generali Wellion, Tecnobody Srl, EMAC Srl, Merz Therapeutics, AllyArm Srl). The remaining authors declare no competing interests. The authors confirm that none of the above relationships influenced the design, conduct, or reporting of the present study.
